Serious Adverse Event. 18.1. In the event one or more of the Subjects sustains any Serious Adverse Event related to the Trial, the Principal Investigator shall inform BioCancell and the Medical Center Helsinki Committee and/or the Medical Center management and/or the authorized national health authorities.
Appears in 3 contracts
Samples: Biocancell Therapeutics Inc., Biocancell Therapeutics Inc., Biocancell Therapeutics Inc.
Serious Adverse Event. 18.1. In the event one or more of the Subjects sustains any Serious Adverse Event related to the Trial, the Principal Investigator shall inform BioCancell and the Medical Center Helsinki Committee and/or the Medical Center management and/or the authorized national health authoritiesClinical Trial Site’ IRB.
Appears in 1 contract
Samples: Biocancell Therapeutics Inc.
Serious Adverse Event. 18.1. In the event one or more of the Subjects sustains any Serious Adverse Event related to the Trial, the Principal Investigator shall inform BioCancell and the Medical Center Fund Helsinki Committee and/or the Medical Center Fund management and/or the authorized national health authorities.
Appears in 1 contract
Samples: Biocancell Therapeutics Inc.
Serious Adverse Event. 18.119.1. In the event one or more of the Subjects sustains any Serious Adverse Event related to the Trial, the Principal Investigator shall inform BioCancell and the Medical Center Helsinki Committee and/or the Medical Center management and/or the authorized national health authorities.
Appears in 1 contract
Samples: Biocancell Therapeutics Inc.